期刊
FRONTIERS IN MEDICINE
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2022.1062450
关键词
salvage therapy; COVID-19; immunocompromised; monoclonal antibodies; sotrovimab; nirmatrelvir; ritonavir; remdesivir
COVID-19 in immunocompromised patients is difficult to treat, and the understanding of SARS-CoV-2 interaction with the host immune system and therapy role is limited. The use of monoclonal antibodies and antiviral combinations for viral replication and disease progression is lacking data. Here, we report successful treatment of two COVID-19 patients with positive SARS-CoV-2 RNAemia, who had undergone rituximab treatment for non-Hodgkin lymphoma and granulomatosis with polyangiitis, respectively, using a salvage combination therapy with sotrovimab, remdesivir, and nirmatrelvir/ritonavir.
COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with the host immune system and the role of therapy still remains only partly understood. There are no data regarding the use of monoclonal antibodies and the combination of two antivirals in fighting viral replication and disease progression. We report the cases of two patients, both treated with rituximab for non-Hodgkin lymphoma and granulomatosis with polyangiitis, respectively, and both hospitalized for COVID-19 with positive SARS-CoV-2 RNAemia, who were successfully treated with a salvage combination therapy with sotrovimab, remdesivir and nirmatrelvir/ritonavir.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据